Biopharmaceutical firm Cobra Biologics and the University of Manchester have been awarded £217k from Innovate UK/ Biotechnology and Biological Sciences Research Council (BBSRC) to jointly develop a protein expression optimisation platform for the robust production of biologics.
The PeriTune project will utilise the tuneable gene expression control technology RiboTite, developed at the University of Manchester, and the expertise in bioprocessing scale up at Keele University Science and Business Park-based Cobra Biologics.
The platform should enable key bottlenecks and manufacturability challenges of recombinant proteins used in both biopharmaceutical medicines and industrial biotechnology to be addressed.
Dr Daniel Smith, CSO Cobra Biologics, said: “We are looking forward to collaborating closely with Dr Neil Dixon, his team at the University of Manchester, and their innovative RiboTite technology. This is a very exciting project for Cobra, as it has the potential to expand our current microbial production toolbox, providing alternative routes for controlling protein expression for a wide range of potential new protein-based therapeutics.”
Dr Neil Dixon, University of Manchester, commented: “We are very pleased that this funding will enable us to collaborate with Cobra Biologics and support the on-going translation of our research into industry.
“We believe the technology platform could make a significant impact on issues involved in the production of biopharmaceutical medicines and other industrial biotechnology products, which in turn would reduce manufacturing costs and enable de-risking of early product development projects.”
PeriTune is one of 23 projects sharing almost £20 million from the Innovate UK/BBSRC supported Industrial Biotechnology Catalyst.